Pancreatic Cancer: Current Concepts in Invasion and Metastasis

Chiblak, Sara; Abdollahi, Amir

doi:10.5772/28175

Cited by 2 publications

(2 citation statements)

References 141 publications

(112 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pancreatic cancer (PC) is one of the most aggressive and lethal type of cancer in humans because most of the patients die within the first year of diagnosis and just 6% of them Review Article survive five years. Since PC usually indicates no symptoms and is insensitive to existing therapies, approximately 85% of these patients develop metastasis when the disease is first determined [1][2][3][4][5][6]. Thus, it is not surprising that PC is still remains one of the most challenging problem in the scientific world.…”

Section: Introductionmentioning

confidence: 99%

The Importance of Targeted Drug Delivery Systems on Pancreatic Cancer

Kaleli

2014

BJAST

View full text Add to dashboard Cite

Pancreatic cancer (PC) is the fourth type of cancer-related death in the world. There is estimated 45,220 new cases of PC will be diagnosed and 38,460 people will be passed away from the disease in the near future. The absence of diagnostic and prognostic markers and also unresponsiveness to current therapies including radiation and chemotherapies are major barriers against successful therapy even in the initial stage. The current therapies is not sufficient to provide effective treatment for PC patients due torapiddrug solubility and metabolism, insufficient drug concentration at the specific site and adverse side effects. To eliminate this disadvantages, nanoparticle based drug delivery systems have been investigated.In this review, we try to reveal the genetic and molecular mechanism which cause PC and emphasize the importance of targeted drug delivery systems for the disease.

show abstract

Section: Introductionmentioning

confidence: 99%

The Importance of Targeted Drug Delivery Systems on Pancreatic Cancer

Kaleli

2014

BJAST

View full text Add to dashboard Cite

show abstract

“…enhance invasiveness have been elucidated (6,7,(9)(10)(11). For example, several studies have pointed to the importance of Matrix Metalloproteinases (MMPs) and the tumor microenvironment in regulating invasion (12)(13)(14). Further, urokinase-type plasminogen activator (uPA) and urokinasetype plasminogen activator receptor (uPAR) in the stroma are known to promote invasion of pancreatic cancer via activation of MMPs (15,16).…”

mentioning

confidence: 99%

Combination Treatment of Biochanin A and Atorvastatin Alters Mitochondrial Bioenergetics, Modulating Cell Metabolism and Inducing Cell Cycle Arrest in Pancreatic Cancer Cells

DESAI,

TADINADA,

SHAGHAGHI

et al. 2024

Anticancer Res

View full text Add to dashboard Cite

Background/Aim: Pancreatic cancer is an aggressive type of cancer, with a dismally low survival rate of <5%. FDAapproved drugs like gemcitabine have shown little therapeutic success, prolonging survival by a mere six months. Isoflavones, such as biochanin A and daidzein, are known to exhibit anticancer activity, whereas statins reportedly have anti-proliferative effects. This study investigated the effects of combination treatment of biochanin A and atorvastatin on pancreatic cancer cells. Materials and Methods: Pancreatic cancer cells AsPC-1, PANC-1, and MIA PaCa-2 were procured from ATCC. The cell viability studies were carried out using MTT & cell count assays. Flow cytometry was used to study cell apoptosis whereas cell metabolism studies were carried out using the Seahorse Mito stress test and XF-PMP assay. The effects of treatment on cell signaling pathways & cell cycle associated proteins were investigated using western blot whereas invasiveness of cancer cells was evaluated using gelatin zymography. Results: The combination treatment decreased the survival and enhanced proapoptotic responses compared to single treatments in the pancreatic cancer cells. In PANC-1 cells, the combination treatment decreased invasiveness, reduced expression of activated STAT3 and expression of critical mediators of cell cycle progression. Furthermore, the combination treatment induced a differential inhibition of respiratory complexes in the pancreatic cancer cells. Conclusion: The combination treatment of biochanin A and atorvastatin exerts enhanced anti-cancer effects, inducing apoptosis, down-regulating cell cycle associated proteins and invasiveness in pancreatic cancer cells and merits further investigation for new, improved treatments for pancreatic cancer.Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States and has a very poor prognosis (1). In 2024, an estimated 66,440 new cases and 51,750 deaths are expected to be recorded due to this devastating disease (1). The poor prognosis associated with pancreatic cancer may be attributed to the limited effectiveness of current chemotherapies due to apoptosis resistance of cells in the primary tumor. The highly aggressive nature of the cancer cells and lack of biomarkers for early diagnosis of pancreatic cancer undoubtedly also contribute (2).Apoptosis resistance in pancreatic cancer has been attributed to several factors including impairment of TRAILmediated mechanisms promoting apoptosis and decreased TRAIL receptor expression (3-5). The low survival rate of pancreatic cancer can be mainly attributed to its highly aggressive nature. The tumor cells tend to metastasize to distant organs like the lungs and liver, which explains the primary tumor cells' resistance to anoikis (6-8). Some underlying mechanisms that promote resistance to anoikis and 2307

show abstract

Pancreatic Cancer: Current Concepts in Invasion and Metastasis

Cited by 2 publications

References 141 publications

The Importance of Targeted Drug Delivery Systems on Pancreatic Cancer

The Importance of Targeted Drug Delivery Systems on Pancreatic Cancer

Combination Treatment of Biochanin A and Atorvastatin Alters Mitochondrial Bioenergetics, Modulating Cell Metabolism and Inducing Cell Cycle Arrest in Pancreatic Cancer Cells

Contact Info

Product

Resources

About